Published December 1, 2008 | Version v1
Journal article

Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey

  • 1. Dokuz Eylul University Medical School, Department of Radiation Oncology, Izmir (Turkey)
  • 2. Ankara Oncology Hospital, Department of Radiation Oncology, Ankara (Turkey)
  • 3. Izmir Private Oncology Center, Izmir (Turkey)
  • 4. Okmeydani Training and Research Hospital, Department of Radiation Oncology, Istanbul (Turkey)
  • 5. Ankara University Medical School, Department of Radiation Oncology, Ankara (Turkey)
  • 6. Ege University Medical School, Department of Radiation Oncology, Izmir (Turkey)
  • 7. Gazi University Medical School, Department of Radiation Oncology, Ankara (Turkey)
  • 8. Akdeniz University Medical School, Department of Radiation Oncology, Antalya (Turkey)
  • 9. Hacettepe University Medical School, Department of Radiation Oncology, Ankara (Turkey)
  • 10. Uludag University Medical School, Department of Radiation Oncology, Bursa (Turkey)
  • 11. Gaziantep University Medical School, Department of Radiation Oncology, Gaziantep (Turkey)
  • 12. Istanbul University Cerrahpasa Medical School, Department of Radiation Oncology, Istanbul (Turkey)
  • 13. Trakya University Medical School, Department of Radiation Oncology, Edirne (Turkey)
  • 14. Baskent University Medical School, Department of Radiation Oncology, Adana (Turkey)
  • 15. Marmara University Medical School, Department of Radiation Oncology, Istanbul (Turkey)
  • 16. Guelhane Military Medical Academy, Department of Radiation Oncology, Ankara (Turkey)
  • 17. Metropolitan Florence Nightingale Hospital, Department of Radiation Oncology, Istanbul (Turkey)

Description

Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were '≥ IB' disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2008.03.035

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2008.03.035;
PII
S0360-3016(08)00541-5;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
72
Journal Issue
5
Journal Page Range
p. 1530-1537
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
40047695
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BRACHYTHERAPY; CARCINOMAS; CHEMOTHERAPY; COMBINED THERAPY; HISTOLOGY; IRRADIATION; LUNGS; PATIENTS; RECOMMENDATIONS; SURGERY
Descriptors DEC
BODY; DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; RESPIRATORY SYSTEM; THERAPY

Optional Information

Copyright
Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.